FRANKFURT, May 4 (Reuters) - Genetic-testing company Qiagen (QGEN.DE) (QGEN.O) posted a 9 percent gain in first-quarter adjusted net earnings, slightly better than expected, helped by takeovers and higher demand for testing kits for the cervical-cancer virus.
